Oyaga-Ruidiaz K, Gómez-Díaz M, Erazo-Muñoz M, Benavides-Cruz J

Language: Spanish
References: 30
Page: 87-93
PDF size: 467.75 Kb.

ABSTRACT

Introduction: chronic pain has a negative impact on several dimensions of human life. The evidence base for the use of lidocaine in outpatient settings for the management of chronic pain is limited. Objective: to evaluate chronic pain control and its impact on aspects of daily life in patients receiving outpatient treatment with lidocaine infusions. Material and methods: this observational study examined a cohort of 24 patients with chronic pain who received outpatient treatment with lidocaine infusions for a period of eight weeks. Pain intensity and interference with aspects of daily life were assessed using the Brief Pain Inventory. Outcomes were analyzed by repeated measures ANOVA and paired samples t-test. Results: a significant reduction was observed in the minimal pain score in the last 24 hours and in interference with general activities (p ≤ 0.005), walking (p ≤ 0.005) and work (p ≤ 0.001). Furthermore, opioid use was reduced by 12.5%. Conclusions: ambulatory lidocaine infusion has been demonstrated to be an effective method for reducing pain and the interference of pain with some activities of daily living, as well as the use of opioids. Therefore, the use of lidocaine may be considered as a potential adjunctive therapy in the multimodal management of chronic pain.

REFERENCES

1. Raja SN, Carr DB, Cohen M, et al. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain. 2020;161:1976-1982. doi: 10.1097/j.pain.0000000000001939

2. Dorner TE. Pain and chronic pain epidemiology: implications for clinical and public health fields. Wien Klin Wochenschr. 2018;130:1-3. doi: 10.1007/s00508-017-1301-0

3. St. Sauver JL, Warner DO, Yawn BP, Jacobson DJ, McGree ME, Pankratz JJ, et al. Why patients visit their doctors: assessing the most prevalent conditions in a defined American population. Mayo Clin Proc. 2013;88:56-67. doi: 10.1016/j.mayocp.2012.08.020

4. Cohen SP, Vase L, Hooten WM. Chronic pain: an update on burden, best practices, and new advances. Lancet. 2021;397:2082-2097. doi: 10.1016/S0140-6736(21)00393-7.

5. Vos T, Abajobir AA, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211-1259. doi: 10.1016/S0140-6736(17)32154-2.

6. Andrews P, Steultjens M, Riskowski J. Chronic widespread pain prevalence in the general population: a systematic review. European Journal of Pain (United Kingdom). 2018;22:5-18. doi: 10.1002/ejp.1090.

7. Rikard SM, Strahan AE, Schmit KM, Guy GP. Chronic pain among adults — United States, 2019-2021. MMWR Morb Mortal Wkly Rep. 2023;72:379-385. doi: 10.15585/mmwr.mm7215a1.

8. Díaz R, Marulanda F, Sáenz X. Estudio epidemiológico del dolor crónico en Caldas, Colombia (Estudio DOLCA). Acta Méd Colomb. 2009;34:96-102. Recuperado de: https://www.redalyc.org/articulo.oa?id=163113826002

9. Timmerman L, Stronks DL, Groeneweg JG, Huygen FJ. Prevalence and determinants of medication non-adherence in chronic pain patients: a systematic review. Acta Anaesthesiol Scand. 2016;60:416-431. doi: 10.1111/aas.12697.

10. Iacob E, Hagn EE, Sindt J, et al. Tertiary care clinical experience with intravenous lidocaine infusions for the treatment of chronic pain. Pain Med. 2018;19:1245-1253. doi: 10.1093/pm/pnx167.

11. Hand BN, Velozo CA, Krause JS. Measuring the interference of pain on daily life in persons with spinal cord injury: a Rasch-validated subset of items from the Brief Pain Inventory interference scale. Aust Occup Ther J. 2018;65:405-411. doi: 10.1111/1440-1630.12493.

12. Vacher E, Kosela M, Song-Smith C, Morell-Ducos F, Fayaz A. Lidocaine infusions in chronic pain management: a prospective case series analysis. Br J Pain. 2022;16:270-280. doi: 10.1177/20494637211054198

13. Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain. 2004;20:309-318. doi: 10.1097/00002508-200409000-00005.

14. Badia X, Muriel C, Gracia A, Núñez-Olarte JM, Perulero N, Gálvez R, et al. Validación española del cuestionario Brief Pain Inventory en pacientes con dolor de causa neoplásica. Med Clin (Barc). 2003;120:52-59. doi: 10.1016/s0025-7753(03)73601-x.

15. Wilderman I, Pugacheva O, Perelman V, Wansbrough MCT, Voznyak Y, Zolnierczyk L. Repeated intravenous lidocaine infusions for patients with fibromyalgia: higher doses of lidocaine have a stronger and longer-lasting effect on pain reduction. Pain Med. 2020;21:1230-1239. doi: 10.1093/pm/pnz251.

16. McCarthy GC, Megalla SA, Habib AS. Impact of intravenous lidocaine infusion on postoperative analgesia and recovery from surgery: a systematic review of randomized controlled trials. Drugs. 2010;70:1149-1163. doi: 10.2165/10898560-000000000-00000.

17. Shao C, Lin L, Chen M, Wang N, Shangguan W. The effect of lidocaine intraoperative infusion on quality of postoperative sleep in patients undergoing thyroidectomy: a randomized controlled trial. BMC Anesthesiol. 2023;23:158. doi: 10.1186/s12871-023-02109-w.

18. Vigneault L, Turgeon AF, Coté D, et al. Perioperative intravenous lidocaine infusion for postoperative pain control: a meta-analysis of randomized controlled trials. Can J Anesth. 2011;58:22-37. doi: 10.1007/s12630-010-9407-0.

19. Gupta H, Patel A, Eswani Z, Moore P, Steib M, Lee C, et al. Role of intravenous lidocaine infusion in the treatment of peripheral neuropathy. Orthop Rev (Pavia). 2021;13:25567. doi: 10.52965/001C.25567.

20. Mooney JJ, Pagel PS, Kundu A. Safety, tolerability, and short-term efficacy of intravenous lidocaine infusions for the treatment of chronic pain in adolescents and young adults: a preliminary report. Pain Med. 2014;15:820-825. doi: 10.1111/pme.12333.

21. Kim YC, Castañeda AM, Lee CS, Jin HS, Park KS, Moon JY. Efficacy and safety of lidocaine infusion treatment for neuropathic pain: a randomized, double-blind, and placebo-controlled study. Reg Anesth Pain Med. 2018;43:415-424. doi: 10.1097/AAP.0000000000000741.

22. Kiani CS, Hunt RW. Lidocaine continuous subcutaneous infusion for neuropathic pain in hospice patients: safety and efficacy. J Pain Palliat Care Pharmacother. 2021;35:52-62. doi: 10.1080/15360288.2020.1852357.

23. Przeklasa-Muszy?ska A, Kocot-Kepska M, Dobrogowski J, Wiatr M, Mika J. Intravenous lidocaine infusions in a multidirectional model of treatment of neuropathic pain patients. Pharmacol Rep. 2016;68:1069-1075. doi: 10.1016/j.pharep.2016.06.010.

24. Anghelescu DL, Morgan KJ, Frett MJ, et al. Lidocaine infusions and reduced opioid consumption—Retrospective experience in pediatric hematology and oncology patients with refractory pain. Pediatr Blood Cancer. 2021;68:e29215. doi: 10.1002/pbc.29215.

25. Castro I, Carvalho P, Vale N, Monjardino T, Mourao J. Systemic anti-inflammatory effects of intravenous lidocaine in surgical patients: a systematic review and meta-analysis. J Clin Med. 2023;12:3772. doi: 10.3390/jcm12113772.

26. Vlainich R, Issy AM, Sakata RK. Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clin J Pain. 2011;27:285-288. doi: 10.1097/AJP.0b013e3181ffbfde.

27. Marret E, Rolin M, Beaussier M, Bonnet F. Meta-analysis of intravenous lidocaine and postoperative recovery after abdominal surgery. Br J Surg. 2008;95:1331-1338. doi: 10.1002/bjs.6375.

28. de Souza MF, Kraychete DC. A acao analgésica da lidocaína intravenosa no tratamento da dor cronica: uma revisao de literatura. Rev Bras Reumatol. 2014;54:386-392. doi: 10.1016/j.rbr.2014.01.010.

29. Striebel J, Ruppen W, Schneider T. Simultaneous application of lidocaine and ketamine during ambulatory infusion therapy: a retrospective analysis. Pain Manag. 2023;13:539-553. doi: 10.2217/pmt-2023-0037.

30. Horvat S, Staffhorst B, Cobben JHMG. Intravenous lidocaine for treatment of chronic pain: a retrospective cohort study. J Pain Res. 2022;15:3459-3467. doi: 10.2147/JPR.S379208.